IP Library Granted Patent US 9,233,113
Granted Patent B2
US 9,233,113 · App. 12/820,398 · Granted Jan 12, 2016

Method for treatment of diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,113
App. No.
12/820,398
Granted
Jan 12, 2016
Kind
B2
Abstract

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.

Claims (6)

1. A method of treating diabetic nephropathy in a human in need thereof comprising orally administering to the human a vascular-hyperpermeability-inhibiting amount of danazol or a pharmaceutically acceptable salt thereof, wherein the hyperpermeability-inhibiting amount is from 1 mg to 100 mg per day.

2. The method of claim 1 wherein administration of the danazol or a pharmaceutically acceptable salt thereof, is commenced immediately upon diagnosis of the diabetic nephropathy.

3. The method of claim 1 wherein the vascular-hyperpermeability-inhibiting amount is from 10 mg to 90 mg of danazol or a pharmaceutically acceptable salt thereof per day.

4. The method of claim 1 wherein the vascular-hyperpermeability-inhibiting amount of danazol or a pharmaceutically acceptable salt thereof is administered to the human at the appearance of one or more early signs of, or a predisposition to develop, diabetic nephropathy.

5. The method of claim 4 wherein administration of danazol or a pharmaceutically acceptable salt thereof is commenced upon the appearance of hyperfiltration.

6. The method of claim 4 wherein administration of danazol or a pharmaceutically acceptable salt thereof is commenced upon the appearance of microalbuminuria.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2013
From: DMI ACQUISITION CORP.
To: AMPIO PHARMACEUTICALS, INC.
Reel/Frame 031305/0001 →
CORRECTIVE ASSGINMENT TO CORRECT THE ADDRESS OF ASSIGNEE. THE ASSIGNEE HAS SINCED CHANGED LOCATIONS, PREVIOUSLY RECORDED ON REEL 024905 FRAME 0075. ASSIGNOR(S) HEREBY CONFIRMS THE FOLLOWING " AT THE REQUEST OF THE ASSIGNEE DO SELL, ASSIGN AND TRANSFER UNTO SAID ASSIGNEE..." Recorded Jan 19, 2011
From: BAR-OR, DAVID
To: DMI ACQUISITION CORP.
Reel/Frame 025665/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2010
From: BAR-OR, DAVID
To: DMI ACQUISITION CORP.
Reel/Frame 024905/0075 →